[China Pharmaceutical Network Technology News] How to find the presence of tumors at an appropriate time in the early stage is a key factor affecting the therapeutic effect of cancer. Recently, a "tumor catcher" was born, the main application is a new generation of CTC detection technology, through the nano-magnetic beads wrapped with peptides to capture circulating tumor cells in the peripheral blood, so as to achieve early detection of tumors.
Except for a small number of cancers, most of the malignant tumors appear in the epithelial cells of the human body. The epithelial cells that have fallen from the tumor tissue enter the peripheral blood circulation and become circulating tumor cells, which is an important biomarker for tumor detection. These cells are characterized by extremely low and small amounts of blood, and the core technology of tumor trappers is the capture of these tumor cells using peptide nanobead technology.
The market space in the field of cancer has no need to be rumored, and there is a large amount of space and growth space. From the patient's point of view, the biggest need is to find a good doctor and appropriate treatment plan, and the doctor's needs in addition to finding the patients in need, as well as data accumulation and mining in scientific research. From these two aspects, many startup companies have emerged, such as anti-cancer guards, anti-cancer circles, excellent medical care, medical assistants, Xinyu information, Sipai network, and zero-gram technology.
However, the key factor affecting the efficacy of cancer treatment is how to detect the presence of tumors at an appropriate time in the early stages. In this regard, liquid biopsy technology is currently the hottest area. A recent "tumor catcher", the main application is a new generation of CTC detection technology, through the nano-magnetic beads wrapped with peptides to capture circulating tumor cells in the peripheral blood, so as to achieve early detection of tumors.
The principle of this product is as follows: except for a small number of cancers, most of the malignant tumors appear in the epithelial cells of the human body, and the epithelial cells that have fallen off from the tumor tissue enter the peripheral blood circulation to become circulating tumor cells (Circulating Tumor Cell (CTC)). It is an important biomarker for tumor detection. These cells are characterized by extremely low and small amounts of blood, and the core technology of tumor trappers is the capture of these tumor cells using peptide nanobead technology.
Dr. Hu Zhiyuan studied at the Johns Hopkins School of Medicine in the United States and is deeply influenced by the 4P medical concept, namely Predictive, Preventive, Personalized, and Participatory. Especially for cancer treatment, early prevention screening is even more important.
From the occurrence to the discovery of tumors, it often takes more than 10 years, that is, through the so-called early, middle and late stages. Early detection of tumors and late detection have huge differences in the five-year survival rate of patients. After early detection, active and effective interventions are taken in time, and the five-year survival rate of patients can reach 90%. After the late stage, the five-year survival rate of patients is usually only about 15%. At present, the more commonly used PET-CT technology and other imaging methods can only find and diagnose advanced tumors, and can not accurately identify early tumors. Therefore, early screening of cancer requires technology that can identify smaller tumor tissues, and "tumor catcher" technology It is one of the cutting-edge technologies in this field.
Committed to the accurate discovery of early tumors, the tumor catcher develops a new generation of CTC nano-detection technology
At present, there are already some similar technologies in the market. “Nanotechnology can make magnetic beads smaller and more sensitive,†said the head of the tumor catcher. “And this material is synthesized by our own research and development technology. It can be used to install the identification probe in terms of density, direction and structure. Do precision control."
There are two indicators for measuring the accuracy of tumor cell capture, one is sensitivity and the other is specificity. In layman's terms, it is not only accurate but also false positives for healthy people. Tumor catchers currently have a sensitivity of 92% and a specificity of 90%.
Previously, the tumor catcher has cooperated with many top three hospitals, including the PLA General Hospital, 302 Hospital, 307 Hospital, Peking Union Medical College Hospital, Cancer Hospital of the Chinese Academy of Sciences, and Peking University Cancer Hospital. Moreover, in related clinical trials, the technology of tumor catchers can be applied to lung cancer, liver cancer, colorectal cancer, stomach cancer, esophageal cancer, nasopharyngeal cancer and other major high-grade tumor diseases in China.
In terms of external application, Dr. Hu Zhiyuan said that it is mainly used in cooperation with medical examination institutions for the screening and diagnosis of early cancer. In addition, the main task of the tumor catcher is to develop automated instruments and equipment that can be used directly by medical institutions.
Tumor catchers are also exploring artificial intelligence to identify CTC. The laboratory has developed the layout of artificial intelligence technology and explored more applications of deep learning in cancer. Especially in CTC technology, many key links can be deeply integrated with artificial intelligence. Better promote the development of medical technology.
Except for a small number of cancers, most of the malignant tumors appear in the epithelial cells of the human body. The epithelial cells that have fallen from the tumor tissue enter the peripheral blood circulation and become circulating tumor cells, which is an important biomarker for tumor detection. These cells are characterized by extremely low and small amounts of blood, and the core technology of tumor trappers is the capture of these tumor cells using peptide nanobead technology.
The market space in the field of cancer has no need to be rumored, and there is a large amount of space and growth space. From the patient's point of view, the biggest need is to find a good doctor and appropriate treatment plan, and the doctor's needs in addition to finding the patients in need, as well as data accumulation and mining in scientific research. From these two aspects, many startup companies have emerged, such as anti-cancer guards, anti-cancer circles, excellent medical care, medical assistants, Xinyu information, Sipai network, and zero-gram technology.
However, the key factor affecting the efficacy of cancer treatment is how to detect the presence of tumors at an appropriate time in the early stages. In this regard, liquid biopsy technology is currently the hottest area. A recent "tumor catcher", the main application is a new generation of CTC detection technology, through the nano-magnetic beads wrapped with peptides to capture circulating tumor cells in the peripheral blood, so as to achieve early detection of tumors.
The principle of this product is as follows: except for a small number of cancers, most of the malignant tumors appear in the epithelial cells of the human body, and the epithelial cells that have fallen off from the tumor tissue enter the peripheral blood circulation to become circulating tumor cells (Circulating Tumor Cell (CTC)). It is an important biomarker for tumor detection. These cells are characterized by extremely low and small amounts of blood, and the core technology of tumor trappers is the capture of these tumor cells using peptide nanobead technology.
Dr. Hu Zhiyuan studied at the Johns Hopkins School of Medicine in the United States and is deeply influenced by the 4P medical concept, namely Predictive, Preventive, Personalized, and Participatory. Especially for cancer treatment, early prevention screening is even more important.
From the occurrence to the discovery of tumors, it often takes more than 10 years, that is, through the so-called early, middle and late stages. Early detection of tumors and late detection have huge differences in the five-year survival rate of patients. After early detection, active and effective interventions are taken in time, and the five-year survival rate of patients can reach 90%. After the late stage, the five-year survival rate of patients is usually only about 15%. At present, the more commonly used PET-CT technology and other imaging methods can only find and diagnose advanced tumors, and can not accurately identify early tumors. Therefore, early screening of cancer requires technology that can identify smaller tumor tissues, and "tumor catcher" technology It is one of the cutting-edge technologies in this field.
Committed to the accurate discovery of early tumors, the tumor catcher develops a new generation of CTC nano-detection technology
At present, there are already some similar technologies in the market. “Nanotechnology can make magnetic beads smaller and more sensitive,†said the head of the tumor catcher. “And this material is synthesized by our own research and development technology. It can be used to install the identification probe in terms of density, direction and structure. Do precision control."
There are two indicators for measuring the accuracy of tumor cell capture, one is sensitivity and the other is specificity. In layman's terms, it is not only accurate but also false positives for healthy people. Tumor catchers currently have a sensitivity of 92% and a specificity of 90%.
Previously, the tumor catcher has cooperated with many top three hospitals, including the PLA General Hospital, 302 Hospital, 307 Hospital, Peking Union Medical College Hospital, Cancer Hospital of the Chinese Academy of Sciences, and Peking University Cancer Hospital. Moreover, in related clinical trials, the technology of tumor catchers can be applied to lung cancer, liver cancer, colorectal cancer, stomach cancer, esophageal cancer, nasopharyngeal cancer and other major high-grade tumor diseases in China.
In terms of external application, Dr. Hu Zhiyuan said that it is mainly used in cooperation with medical examination institutions for the screening and diagnosis of early cancer. In addition, the main task of the tumor catcher is to develop automated instruments and equipment that can be used directly by medical institutions.
Tumor catchers are also exploring artificial intelligence to identify CTC. The laboratory has developed the layout of artificial intelligence technology and explored more applications of deep learning in cancer. Especially in CTC technology, many key links can be deeply integrated with artificial intelligence. Better promote the development of medical technology.
Industrial 100Hz LiDAR Solutions
Industrial Laser Distance Sensor of the IT02S & IT03M series are designed for measurements of moving targets. The LiDAR distance sensor is a ToF (Time of Flight) LiDAR sensor capable of measuring the distance to an object as close as 3 centimeters and as far as 15 meters! The LiDAR laser sensor is widely used in many innovative applications on the market, including smart dustbin, unmanned supermarket etc.long distance control system.
Application areas of the sensor are:
> Harsh environments, like outdoors in strong sunlight
> Black surface can be up to 8m
> UAV/Drone Systems
> Intelligent Parking
> Smart Measure Systems
> Intelligent toilet
Industrial Lidar Sensor,Tof Laser Measurement Module,Tof Sensors,Time Of Flight Distance Sensor
Chengdu JRT Meter Technology Co., Ltd , https://www.jrt-measure.com